COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. This change lagged the S&P 500's 1.26% gain on the day. Elsewhere, the Dow saw an upswing ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Shares of Moderna Inc. MRNA inched 0.43% higher to $42.18 Friday, on what proved to be an all-around favorable trading ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

It can take several weeks to bounce back after a bout of COVID-19, but some people develop more persistent problems. The ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

Moderna ( MRNA) was the best-performing stock in the S&P 500 as Barron's called it "too cheap" and named the biotech firm as ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...